Nuvalent submits NDA for lung cancer drug neladalkib

Nuvalent, Inc. reported that on April 7, 2026 it announced submitting a New Drug Application to the U.S. Food and Drug Administration for neladalkib.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Nuvalent, Inc. reported that on April 7, 2026 it announced submitting a New Drug Application to the U.S. Food and Drug Administration for neladalkib. The application covers use in tyrosine kinase inhibitor pre-treated, advanced ALK-positive non-small cell lung cancer.

This step moves neladalkib from clinical development into formal regulatory review, an important stage toward potential U.S. market availability if the FDA later approves the drug.

Positive

Nuvalent submitted a New Drug Application to the FDA for neladalkib in tyrosine kinase inhibitor pre-treated, advanced ALK-positive non-small cell lung cancer, marking an important regulatory milestone that moves the program closer to potential commercialization, subject to future FDA review and decision.

Negative

None.

Insights

Nuvalent advances neladalkib into FDA review with NDA submission.

Nuvalent has submitted a New Drug Application to the U.S. Food and Drug Administration for neladalkib in tyrosine kinase inhibitor pre-treated, advanced ALK-positive non-small cell lung cancer. This signals completion of a key development phase for the program.

While the outcome is not addressed here, an NDA submission typically follows substantial clinical testing and positions a therapy for potential commercial use if approved. Future regulatory decisions will determine whether neladalkib becomes a treatment option for this patient group.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Terms

New Drug Application, ALK-positive non-small cell lung cancer, tyrosine kinase inhibitor, Emerging growth company

4 terms

New Drug Application regulatory

"announced the submission of its New Drug Application to the U.S. Food and Drug Administration"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

ALK-positive non-small cell lung cancer medical

"for neladalkib in tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer"

tyrosine kinase inhibitor medical

"for neladalkib in tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer"

A tyrosine kinase inhibitor is a type of drug that blocks specific proteins in cells that act like on/off switches for growth and survival signals, often used to stop cancer cells from multiplying. For investors, these drugs matter because their clinical trial results, regulatory approvals, safety profiles, and patent status drive sales potential and company valuation—think of them as precision tools whose effectiveness and market exclusivity determine commercial success.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

What did Nuvalent (NUVL) announce regarding neladalkib?

Nuvalent announced it has submitted a New Drug Application to the U.S. Food and Drug Administration for neladalkib. The filing covers use in tyrosine kinase inhibitor pre-treated, advanced ALK-positive non-small cell lung cancer, moving the program into formal regulatory review.

Which condition is targeted by Nuvalent’s drug candidate neladalkib?

Neladalkib is intended for advanced ALK-positive non-small cell lung cancer in patients previously treated with tyrosine kinase inhibitors. This focuses on a specific lung cancer subtype where tumors carry ALK alterations and prior targeted therapy has already been used.

What regulatory step did Nuvalent (NUVL) take with the FDA?

Nuvalent submitted a New Drug Application to the U.S. Food and Drug Administration. This seeks FDA review of neladalkib for tyrosine kinase inhibitor pre-treated, advanced ALK-positive non-small cell lung cancer and represents a key stage after clinical development.

Does Nuvalent’s announcement indicate FDA approval of neladalkib?

The announcement describes submission of a New Drug Application, not an approval. It means Nuvalent has formally asked the U.S. Food and Drug Administration to review neladalkib for a specific lung cancer setting; any approval decision would come later.

What type of SEC filing did Nuvalent use for this neladalkib update?

Nuvalent used a Form 8-K under the "Other Events" section to report the neladalkib update. The filing states that on April 7, 2026, the company announced submitting a New Drug Application to the U.S. Food and Drug Administration for this indication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/07/2026 - 06:33 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 7, 2026

NUVALENT, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-40671	81-5112298
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Nuvalent, Inc.

One Broadway, 14th Floor, Cambridge, Massachusetts 02142

(Address of principal executive offices, including zip code)

(857) 357-7000

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trade Symbol(s)	Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share	NUVL	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On April 7, 2026, Nuvalent, Inc. announced the submission of its New Drug Application to the U.S. Food and Drug Administration for neladalkib in tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			Nuvalent, Inc.

Date:	April 7, 2026	By:	/s/ Deborah A. Miller
			Deborah A. Miller, Ph.D. Chief Legal Officer and Secretary

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Nuvalent submits NDA for lung cancer drug neladalkib